Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
November 21, 2023
Read More
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 9, 2023
Read More
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
November 7, 2023
Read More
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
October 27, 2023
Read More
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
October 26, 2023
Read More
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
October 17, 2023
Read More
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
October 17, 2023
Read More
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
Read More
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
July 26, 2023
Read More
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
May 30, 2023
Read More
Displaying 1 - 10 of 18